for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Anika Therapeutics Inc

ANIK.OQ

Latest Trade

56.96USD

Change

-0.15(-0.26%)

Volume

45,730

Today's Range

56.27

 - 

57.32

52 Week Range

29.08

 - 

59.75

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
57.11
Open
56.75
Volume
45,730
3M AVG Volume
4.38
Today's High
57.32
Today's Low
56.27
52 Week High
59.75
52 Week Low
29.08
Shares Out (MIL)
13.78
Market Cap (MIL)
787.14
Forward P/E
32.70
Dividend (Yield %)
--

Next Event

Q3 2019 Anika Therapeutics Inc Earnings Call

Latest Developments

More

Anika Therapeutic Reports Q2 EPS Of $0.67

Anika Therapeutics Entered Into An Accelerated Share Repurchase Agreement With Morgan Stanley & Co. Llc

Anika Q1 Earnings Per Share $0.31

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Anika Therapeutics Inc

Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company's therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company's ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.

Industry

Biotechnology & Drugs

Contact Info

32 Wiggins Ave

+1.781.4579000

https://www.anikatherapeutics.com/

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

2.150

2017

1.960

2018

1.270

2019(E)

1.747
Price To Earnings (TTM)
27.82
Price To Sales (TTM)
7.23
Price To Book (MRQ)
3.14
Price To Cash Flow (TTM)
22.37
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
11.04
Return on Equity (TTM)
10.59

Latest News

Latest News

BRIEF-Anika Therapeutics Q1 Loss Per Share $0.46

* Q1 EARNINGS PER SHARE VIEW $0.16 -- THOMSON REUTERS I/B/E/S

BRIEF-Joseph Darling Named CEO And Director Of Anika Therapeutics

* JOSEPH DARLING NAMED CEO AND DIRECTOR OF ANIKA THERAPEUTICS

BRIEF-Anika Q4 Earnings Per Share $0.53

* ANIKA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Anika Therapeutics Announces Strategic Collaboration With The Institute Of Integrative Biology

* ANIKA THERAPEUTICS ANNOUNCES STRATEGIC COLLABORATION WITH THE INSTITUTE OF INTEGRATIVE BIOLOGY AT THE UNIVERSITY OF LIVERPOOL TO DEVELOP AN INNOVATIVE THERAPY FOR OSTEOARTHRITIS Source text for Eikon: Further company coverage:

BRIEF-Anika Therapeutics Expands Strategic Collaboration With Institute For Applied Life Sciences

* ANIKA THERAPEUTICS EXPANDS STRATEGIC COLLABORATION WITH THE INSTITUTE FOR APPLIED LIFE SCIENCES (IALS) AT THE UNIVERSITY OF MASSACHUSETTS AMHERST TO DEVELOP INNOVATIVE THERAPY FOR RHEUMATOID ARTHRITIS Source text for Eikon: Further company coverage:

BRIEF-Anika Announces FDA 510(K) Clearance For Its Injectable HA-Based Bone Repair Treatment

* ANIKA ANNOUNCES FDA 510(K) CLEARANCE FOR ITS INJECTABLE HA-BASED BONE REPAIR TREATMENT

BRIEF-Anika reports Q3 earnings per share $0.46

* Q3 revenue rose 5 percent to $27.2 million Source text for Eikon: Further company coverage:

BRIEF-Anika completes enrollment in second pivotal phase III trial of cingal

* Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis

BRIEF-Anika announces forthcoming appointment of Thomas Finnerty as chief human resources officer

* Anika announces the forthcoming appointment of Thomas M. Finnerty as chief human resources officer Source text for Eikon: Further company coverage:

BRIEF-Anika Therapeutics announces regulatory approval for Monovisc® in Australia

* Anika announces regulatory approval for Monovisc® in Australia for the treatment of pain associated with osteoarthritis of all synovial joints

BRIEF-Kayne Anderson Rudnick Investment Management Llc reports 11.49 pct passive stake in Anika Therapeutics Inc as of August 08, 2017 - SEC filing

* Kayne anderson rudnick investment management llc reports 11.49 percent passive stake in anika therapeutics inc as of august 08, 2017 - sec filing Source text - (http://bit.ly/2fqZxZ8) Further company coverage:

BRIEF-Anika announces appointment of Joseph Darling as president

* Anika therapeutics - co's ceo dr. Charles h. Sherwood who served as president, plans to transition role to darling, while continuing tenure as ceo Source text for Eikon: Further company coverage:

BRIEF-Anika announces regulatory approval for Monovisc in India

* Anika announces regulatory approval for Monovisc in India for the treatment of pain associated with osteoarthritis of all synovial joints Source text for Eikon: Further company coverage:

BRIEF-Anika announces $5 mln milestone payment from U.S. commercial sales of Monovisc

* Anika announces $5 million milestone payment from U.S. Commercial sales of Monovisc

BRIEF-Anika Therapeutics expects to complete supplemental phase III trial of CINGAL in 2018

* Anika announces first patient enrolled in supplemental phase III trial of CINGAL for the treatment of knee pain associated with osteoarthritis

BRIEF-Anika Therapeutics reports Q1 earnings per share $0.37

* Q1 earnings per share view $0.38 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Anika Therapeutics posts Q4 earnings per share $0.54

* Anika reports fourth quarter and full year 2016 financial results

BRIEF-Anika Q3 earnings per share $0.59

* Q3 earnings per share view $0.47 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up